Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Ky-Youb Nam, PhD, Jeejin Im, June H-J H-J Han, Kyu-Tae Kim, PhD, Jeong-Hyeok Yoon, PhD, Hanna Cho, PhD, Seung-Hye Choi, PhD, David Young, MD, Bao Nguyen, Ruiqi Zhu, PhD, Li Li, MD,PhD, Donald Small, MD, PhD, Taebo Sim, PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139044

Published: 2020

Journal Articles

FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study

Patrick A. Brown, MD, John Kairalla, Joanne M. Hilden, MD, Zoann Eckert Dreyer, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Cindy Wang, MS, Meenakshi Devidas, PhD, William L. Carroll, MD, Elizabeth A. Raetz, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD, Michael J. Borowitz, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 1293.

https://doi.org/10.1182/blood-2019-130564

Published: 2019

Journal Articles

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

Jaesung Seo, PhD, Li Li, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 3759.

https://doi.org/10.1182/blood-2019-130339

Published: 2019

Journal Articles

DOCK2 Expression Affects Leukemogenesis and Disease Progression in a Murine Model of FLT3/ITD Acute Myeloid Leukemia

Min Wu, PhD, Li Li, MD PhD, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2019) 134 (Supplement_1): 2534.

https://doi.org/10.1182/blood-2019-129157

Published: 2019

Journal Articles

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Ruiqi Zhu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Amy S. Duffield, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 2564.

https://doi.org/10.1182/blood-2019-131635

Published: 2019

Journal Articles

The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML

Aksinija A Kogan, BS, MS, Michael Topper, BS, Susannah C Shissler, BS, Michael S Lee, BS, Dominique R Bollino, BS, Eun Yong Choi, Rena G Lapidus, PhD, Li Li, MD PhD, Donald Small, MD PhD, Maria R. Baer, MD, Tonya J Webb, PhD, Stephen Baylin, MD, Feyruz V. Rassool, BSc, PhD

Blood (2018) 132 (Supplement 1): 3886.

https://doi.org/10.1182/blood-2018-99-117294

Published: 2018

Journal Articles

Combinatorial Approaches to Overcome Plasma Protein Inhibition of FLT3 Tyrosine Kinase Inhibitors

David J Young, MD PhD, Jun O Liu, PhD, Donald Small, MD PhD

Blood (2018) 132 (Supplement 1): 1362.

https://doi.org/10.1182/blood-2018-99-118820

Published: 2018

Journal Articles

DOCK2 Knockdown Mitigates Disease Progression in Murine Models Harboring a FLT3/ITD Mutation

Min Wu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2017) 130 (Supplement 1): 1216.

https://doi.org/10.1182/blood.V130.Suppl_1.1216.1216

Published: 2017

Journal Articles

A Novel Method for Overcoming Plasma Protein Inhibition of FLT3 Tyrosine Kinase Inhibitors

David J Young, MD PhD, Donald Small, MD PhD

Blood (2017) 130 (Supplement 1): 1241.

https://doi.org/10.1182/blood.V130.Suppl_1.1241.1241

Published: 2017

Journal Articles

FLT3/ITD Cooperates with Rac1/DOCK2 to Modulate the Sensitivity of Leukemic Cells to Chemotherapeutic Agents Via Regulation of DNA Repair Pathways

Min Wu, PhD, Li Li, PhD, Max Hamaker, BA, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2016) 128 (22): 2732.

https://doi.org/10.1182/blood.V128.22.2732.2732

Published: 2016

Journal Articles

Pathways Relevant to AML Pathogenesis Targeting the Hematopoietic-Specific Cebpa +37 Kb Enhancer

Stacy Cooper, MD, Hong Guo, MD PhD, Justin Thomas, Jay L. Hess, MD PhD, Peter D. Aplan, MD, Donald Small, MD PhD, Alan D. Friedman, MD

Blood (2016) 128 (22): 2691.

https://doi.org/10.1182/blood.V128.22.2691.2691

Published: 2016

Journal Articles

Arsenic Trioxide Synergizes with FLT3 Tyrosine Kinase Inhibitors to Kill FLT3-ITD + Leukemic Cells through Depressed Production and Degradation of FLT3 Protein

Kozo Nagai, MD PhD, Lihong Hou, MD PhD, Li Li, MD PhD, Bao Nguyen, M.S., Courtney M Shirley, PhD, Hayley S Ma, PhD, Mark J. Levis, MD PhD, Amy S. Duffield, MD PhD, Donald Small, MD PhD

Blood (2016) 128 (22): 1568.

https://doi.org/10.1182/blood.V128.22.1568.1568

Published: 2016

Journal Articles

FLT3 TKI Are Differentially Affected By Both Plasma Binding and Stromal Survival Factors

Young J David, MD PhD, Hayley S Ma, PhD, Donald Small, MD PhD

Blood (2016) 128 (22): 1570.

https://doi.org/10.1182/blood.V128.22.1570.1570

Published: 2016

Journal Articles

Signaling Adaptation to TKI Treatment Reactivates ERK Signaling in FLT3/ITD Leukemia

Joshua Kyle Bruner, Li Li, MD PhD, Hayley S Ma, PhD, Alice Can Ran Qin, Mark J. Levis, MD PhD, Keith W. Pratz, MD, Christine A. Pratilas, MD, Donald Small, MD PhD

Blood (2016) 128 (22): 33.

https://doi.org/10.1182/blood.V128.22.33.33

Published: 2016

Journal Articles

DOCK2 Regulates DNA Damage Response and Modulates the Sensitivity to Chemotherapeutic Agents in FLT3/ITD Leukemic Cells

Min Wu, PhD, Li Li, PhD, Max Hamaker, BA, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2015) 126 (23): 3668.

https://doi.org/10.1182/blood.V126.23.3668.3668

Published: 2015

Journal Articles

FLT3 Inhibition and Retinoid Signaling Overcome Stromal Protection to Target FLT3/ITD-Expressing Leukemia Stem Cells in the Bone Marrow Microenvironment

Hayley S Ma, PhD, Megan E McCray, BA, Courtney M Shirley, PhD, Amy S. Duffield, MD PhD, J Kyle Bruner, Li Li, PhD, Bao Nguyen, M.S., Sarah Greenblatt, PhD, Eric Jung, BS, Peter D. Aplan, MD, Richard J Jones, MD, Donald Small, MD PhD, Gabriel Ghiaur, MD PhD

Blood (2015) 126 (23): 790.

https://doi.org/10.1182/blood.V126.23.790.790

Published: 2015

Journal Articles

Mouse Modeling of GATA2 Related MDS/AML

Lisa J. McReynolds, MD PhD, Peter D. Aplan, MD, Donald Small, MD PhD, Li Ding, MD, Kirby D. Johnson, Emery H Bresnick, PhD, Steven M. Holland, MD

Blood (2015) 126 (23): 2855.

https://doi.org/10.1182/blood.V126.23.2855.2855

Published: 2015

Journal Articles

A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations

Colleen E. Annesley, MD, Amy S. Duffield, MD PhD, Rachel E. Rau, MD, Gregory McCarty, Daniel Magoon, Li Li, MD PhD, Vicki Huff, PhD, Donald Small, MD PhD, David Loeb, MD PhD, Patrick Brown, MD

Blood (2015) 126 (23): 312.

https://doi.org/10.1182/blood.V126.23.312.312

Published: 2015

Journal Articles

Genetic and Pharmacologic Notch4 Inhibition Synergizes with FLT3 Tyrosine Kinase Inhibition in Vitro to More Effectively Eliminate FLT3/ITD-Positive Leukemia Cells

Courtney M. Shirley, PhD, S. Haihua Chu, PhD, Yandan Yang, PhD, George W. Wright, PhD, Louis M. Staudt, MD PhD, Donald Small, MD PhD

Blood (2014) 124 (21): 3583.

https://doi.org/10.1182/blood.V124.21.3583.3583

Published: 2014

Journal Articles

DOCK2 Interacts with FLT3 and Modulates the Survival of FLT3-Expressing Leukemia Cells

Min Wu, PhD, Max Hamaker, BA, Li Li, PhD, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2014) 124 (21): 3584.

https://doi.org/10.1182/blood.V124.21.3584.3584

Published: 2014

NARROW

PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

DOCK2 Expression Affects Leukemogenesis and Disease Progression in a Murine Model of FLT3/ITD Acute Myeloid Leukemia

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML

Combinatorial Approaches to Overcome Plasma Protein Inhibition of FLT3 Tyrosine Kinase Inhibitors

DOCK2 Knockdown Mitigates Disease Progression in Murine Models Harboring a FLT3/ITD Mutation

A Novel Method for Overcoming Plasma Protein Inhibition of FLT3 Tyrosine Kinase Inhibitors

FLT3/ITD Cooperates with Rac1/DOCK2 to Modulate the Sensitivity of Leukemic Cells to Chemotherapeutic Agents Via Regulation of DNA Repair Pathways

Pathways Relevant to AML Pathogenesis Targeting the Hematopoietic-Specific Cebpa +37 Kb Enhancer

Arsenic Trioxide Synergizes with FLT3 Tyrosine Kinase Inhibitors to Kill FLT3-ITD + Leukemic Cells through Depressed Production and Degradation of FLT3 Protein

FLT3 TKI Are Differentially Affected By Both Plasma Binding and Stromal Survival Factors

Signaling Adaptation to TKI Treatment Reactivates ERK Signaling in FLT3/ITD Leukemia

DOCK2 Regulates DNA Damage Response and Modulates the Sensitivity to Chemotherapeutic Agents in FLT3/ITD Leukemic Cells

FLT3 Inhibition and Retinoid Signaling Overcome Stromal Protection to Target FLT3/ITD-Expressing Leukemia Stem Cells in the Bone Marrow Microenvironment

Mouse Modeling of GATA2 Related MDS/AML

A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations

Genetic and Pharmacologic Notch4 Inhibition Synergizes with FLT3 Tyrosine Kinase Inhibition in Vitro to More Effectively Eliminate FLT3/ITD-Positive Leukemia Cells

DOCK2 Interacts with FLT3 and Modulates the Survival of FLT3-Expressing Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only